Vishi Srinivasan

6223 Avalon Dr, Wilmington, MA.

vs575c12@westpost.net 617-331-5079(C)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Executive Summary
-----------------
5yr of Molecular, in vitro and cell- based assays
developmentexperience in cancer/ virology. More than 2 years
of industry experiencein ISO 9001:2008 certified company.
Proficient invarious molecular biology, virology, immunology
and bioinformatic tools.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
WORK EXPERIENCE
---------------
-Beckman Coulter Genomics, Danvers, MA Jan 2010- present
-Assay Development Lead
Involved in optimization of HIV detection from clinical
samples using bead based technology and quantitative real
time RT-PCR.
-Beckman Coulter Genomics, Danvers, MA. Apr, 2008- 2009
-Senior Development Scientist
Invented transition metal based RNA extraction process from
clinical samples and optimized RNA extraction for an easy
automation. Developed molecular diagnostic assay and process
controls for detection of Epstein Barr virus infection.
Optimized DNA, RNA amplification chemistry using proprietary
DNA polymerases. Made the company save $10,000/mo by
optimizing Realtime PCR assays with heat stable Uracil
DNA Glycosylase.
-Eutrophics Pharmaceutucals, MA. Jul, 2006-2007
-Assay Development Consultant
Developed cell based in vivo assays to screen for apoptotic
inducing small molecules. Worked on Fluorescence
polarizationbased assay for small molecule screen against
antiapoptotic proteins.
-Beth Israel Deaconess Medical Center, MA Feb-Apr,2008
-Postdoctoral Fellow
As part of evaluating HIV vaccine clinical trials in
Monkeys,mice and human beings, worked on identifying
specific cell surface biomarkers involved in mucosal
immunity using FACS multiplex assay.
-Brigham and Women's Hospital, Boston, MA Dec, 2002-2008
-Postdoctoral Fellow
Developed luminescence based HTS cell based assay to screen
for small molecules against poxvirus replication. Also,
developed luminescence based reporter assays involved in
transcriptional regulation of host genes.
Worked on elucidating the role of Kaposi's Sarcoma
associated herpes virus proteins in tumorigenesis.
Developed radioactive based medium throughput assay to
identify amino acid residues which would disrupt viral
protein-DNA interaction involved in latency.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
RESEARCH Technical Skills
-------------------------
Standard molecular biology techniques such as DNA/RNA
purification,PCR, RT-PCR, Realtime PCR, cloning, DNA/RNA
hybridization, basic bioinformatics. Screening of small
molecules and peptides in vitroand in cell based assays.
Recombinant protein expression and affinity purification of
proteins in bacteria, vaccinia (pox), insect cells. Basic
cell culture of primary and secondary cell lines,infection,
propagation of all animal viruses. Immunoassay such as
ELISA, neutralization tests, immunofluorescence,
proliferationassays,immunoprecipitation, cytotoxicity
assays,tetramer staining, ICS, multi fluorimetric staining
FACS analysis. DOE and various statistical analysis.
Conductinganimal model studies in Monkeys, Mice, Chickens
and Guinea pigs.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Managerial Experience
---------------------
Managed and worked as team to develop molecular diagnostic
tools, Radiation and Bio-safety Officer. General laboratory
administration.Assisted and managed technicians, graduate
students, postdoctoral fellows, and summer interns in
research towards completion of research projects.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Professional Board Certifications
---------------------------------
-American College of Veterinary Microbiologists. USA,
Diplomate, Virology 2007
-American Society for Virology, USA, Member 2008
Education
---------
-PhD, University of Illinois, Pathobiology (Micro & Immuno)
GPA.3.94 Dec, 2002
-M.V.Sc (M.S),Biotechnology, Indian Veterinary Research
Institute GPA.8.4 Jul,1998
-B.V.Sc,(B.S) Veterinary Science,Madras Veterinary College
GPA. 3.54 May, 1994
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
SELECTED Research Publications
* Authors contributed equally to the work
1. Srinivasan V., Newcomb K., Barbera AJ., Ballestas M.E.,
Kaye K. (2010). Episome maintenance function of
Latency-Associated Nuclear Antigen of Kaposi's sarcoma-
associated herpes virus is mediated by evolutionarily
conserved mechanisms. Manuscript in preparation for
J Biochem.
2. Kelly-Clarke B., Ballestas ME, Srinivasan V, Barbera AJ,
Komatsu T, Harris T, Kazanjian M, Kaye KM (2007).
Separationof the essential KSHV C-terminal LANA domain into
chromosomebinding and DNA recognition subdomains.
J Virol 81; 4348-4356.
3.You J*., Srinivasan V*., Denis G., Harrington Jr W.,
Kaye K., and Howley P. (2006) The Kaposi's Sarcoma-
AssociatedHerpesvirus Latency-Associated Nuclear Antigen
interacts with bromodomain protein Brd4 on host mitotic
chromosomes. J Virol 80; 8909-8919.
4. Srinivasan V., Schnitzlein W.M., Tripathy D. (2006).
Genetic manipulation of two fowlpox virus late
transcriptionalregulatory elements influences their
ability to direct expression of foreign genes. Virus Res
116; 85-90.
5. Srinivasan V., Tripathy D. N. (2005). The DNA repair
enzyme, CPD-photolyase restores the infectivity of
UV-damaged fowlpox virus isolated from infected scabs
of chickens. Vet Micro 108; 215-223.
6. Srinivasan V*., Komatsu T*., Ballestas M.E., Kaye K.
(2004). Definition of non-palindromic sequence requirements
for LANA1 binding to KSHV DNA. J Virol 78; 14033-38.
7. Srinivasan V., Schnitzlein W. M., Tripathy D. N. (2003).
A consideration of previously uncharacterized fowlpox virus
unidirectional and bi-directional late promoters for
inclusion in homologous recombinant vaccine.
Avian Diseases 47; 286-295.
8. Srinivasan V., Schnitzlein, W. M., Tripathy D. N. (2001)
Fowlpox virus encodes for a novel DNA repair enzyme that
restores infectivity of UV-light damaged virus.
J Virol 75; 1681-88.
9. Suryanarayana V. V. S. , Srinivasan V., Ratish G. (1999)
E-coli expressed proteins as diagnostic reagents for typing
of foot and mouth disease virus. Arch Virol 144; 1701-1712.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx